NCT01543581View on ClinicalTrials.gov

Vismodegib for Treatment of Basal Cell Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

June 30, 2013

Study Completion Date

July 31, 2013

Conditions
Basal Cell Carcinoma
Interventions
DRUG

Vismodegib

Oral vismodegib, 150mg per day for 12 weeks.

DRUG

Placebo

All Listed Sponsors
lead

Abel Torres, MD

OTHER

NCT01543581 - Vismodegib for Treatment of Basal Cell Carcinoma | Biotech Hunter | Biotech Hunter